Disease Overview：Non-Small Cell Lung Cancer（NSCLC）
Non-small cell lung cancer (NSCLC) is the most common histological subtype of lung malignancy, accounting for approximately 85% of all lung cancer cases. It encompasses several distinct pathological variants—including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma—each with unique molecular profiles, clinical behaviors, and therapeutic implications. Diagnosis typically involves high-resolution chest CT, PET-CT staging, bronchoscopy with biopsy, and comprehensive molecular testing (e.g., EGFR, ALK, ROS1, BRAF, PD-L1, and emerging biomarkers such as KRAS G12C and MET exon 14 skipping). Treatment is highly individualized, integrating surgery for early-stage disease, stereotactic body radiotherapy (SBRT), platinum-based chemotherapy, targeted therapy (e.g., osimertinib, alectinib), and immune checkpoint inhibitors (e.g., pembrolizumab, camrelizumab). Prognosis depends significantly on stage at diagnosis, molecular drivers, performance status, and timely access to precision oncology services.
China offers compelling advantages for NSCLC management: its leading oncology centers—such as Fudan University Shanghai Cancer Center and Peking Union Medical College Hospital—boast internationally trained thoracic oncologists, NMPA- and FDA-approved targeted agents often available earlier than in many Western markets, and state-of-the-art infrastructure including digital PET-MRI fusion imaging, robotic-assisted thoracoscopy, and next-generation sequencing platforms. Five-year survival rates for Stage I–II NSCLC exceed 70% in top-tier institutions, supported by robust clinical trial participation and real-world evidence from large-scale cohorts. Crucially, treatment costs are typically 40–60% lower than in the US or Western Europe—without compromising quality—making advanced care accessible without financial hardship.
As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying hospital accreditation, coordinating multidisciplinary tumor board reviews, securing appointments within 72 hours, providing transparent itemized pricing in advance, and offering end-to-end support—from visa assistance and airport transfers to bilingual nursing and post-treatment follow-up coordination.
Non-Small Cell Lung Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Non-Small Cell Lung Cancer (NSCLC) — Respiratory Medicine Department
I. Non-Surgical / Medical Therapies
*Eligibility*: Stage I–IV NSCLC; biomarker-driven selection required (EGFR/ALK/ROS1/BRAF/KRAS/PD-L1 testing mandatory prior to initiation).
- •Targeted Therapy (e.g., Osimertinib, Alectinib)
- *Cost (30-day supply, Grade 3A hospital, USD)*: - Osimertinib (80 mg): $420–$580 - Alectinib (600 mg × 2/day): $390–$520 - *Required Biomarker Testing (per test, USD)*: - NGS panel (50-gene): $280–$360 - PD-L1 IHC (22C3): $85–$110 - *Monitoring Labs (per cycle, USD)*: CBC, LFTs, renal panel: $45–$65
- •Immunotherapy (e.g., Pembrolizumab, Camrelizumab)
- *Cost (200 mg IV q3w, USD)*: - Pembrolizumab: $1,950–$2,300/cycle - Camrelizumab: $720–$940/cycle - *Pre-infusion labs (USD)*: CBC, LFTs, TSH, cortisol: $60–$85
II. Surgical / Interventional Options
*Eligibility*: Clinical Stage I–IIIA (T1–3, N0–1), adequate pulmonary reserve (FEV₁ ≥1.5 L or ≥60% predicted), no distant metastasis on PET-CT + brain MRI.
- •Lobectomy (VATS or robotic-assisted)
- *Preoperative Workup (USD)*: - Pulmonary function tests (PFTs): $75 - PET-CT (whole body): $320–$410 - Brain MRI: $260–$340 - Cardiopulmonary exercise testing (if FEV₁ borderline): $180
- •Sublobar Resection (Wedge/Sleeve)
- *Cost (USD)*: $3,600–$4,900
III. Special/Complex Scenarios
- •Oligometastatic NSCLC (≤3 mets, controlled primary): SBRT to metastases + systemic therapy
- •Locally Advanced (Stage III) with unresectable disease: Concurrent chemoradiation
- Carboplatin/paclitaxel (4 cycles): $1,300–$1,750
IV. Quick Selection Guide
- •Age <70, fit, Stage IB: VATS lobectomy ($5,500 avg) — curative intent, lowest long-term cost.
- •Age ≥75, COPD, Stage IV EGFR+: Osimertinib ($500/mo) — avoids surgery/radiation toxicity.
- •Budget-constrained, PD-L1 ≥50%: Camrelizumab ($830/cycle) — 40% lower than pembrolizumab, same efficacy in Chinese populations.
- •Stage IIIA, borderline resectable: Neoadjuvant chemoimmunotherapy → surgical reassessment — balances cure potential and organ preservation.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Non-Small Cell Lung Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Non-Small Cell Lung Cancer treatment with China top medical destinations:
